BBNX
Beta Bionics, Inc.
Latest Form 4:Sale$102KbyHopman Mark (Chief Commercial Officer) · filed Sep 3, 2026
Beta Bionics, Inc. (BBNX) has 51 SEC Form 4 filings (82 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Sep 3, 2026.
Inside the rolling window, 8 insiders at Beta Bionics, Inc. reported no open-market purchases and 44 open-market sales totaling $3.9M. The most active filer is Chief Financial Officer Feider Stephen with 11 filings. Insiders have net sold $1.6M over the trailing 6 months. The most recent open-market filing is a sale of 5,327 shares by Chief Commercial Officer Hopman Mark, dated Sep 2, 2026, worth $102K.
- Industry:Medical - Equipment & Services
- CEO:Sean T. Saint
- Employees:352
- HQ:Irvine, CA, US
- IPO:2025-01-30
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.9M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Market Cap
$873.5M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Commercial Officer | Sale | 5,327 | $102K | Sep 3 | SEC ↗ | |
Mensinger MikeFirst in 3 months | Chief Product Officer | Sale | 4,375 | $84K | Sep 3 | SEC ↗ |
Russell Steven JonFirst in 3 months | Chief Medical Officer | Sale | 4,221 | $81K | Sep 3 | SEC ↗ |
Saint SeanFirst in 3 months | President & CEO | Sale | 16,867 | $322K | Sep 3 | SEC ↗ |
| Chief Financial Officer | Sale | 6,675 | $128K | Sep 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 5,104 | $87K | Jul 2 | SEC ↗ | |
| Chief Financial Officer | Sale | 4,896 | $83K | Jul 2 | SEC ↗ | |
| Director | Sale | 1,406 | $21K | Jun 25 | SEC ↗ | |
| Chief Commercial Officer | Sale | 1,258 | $19K | Jun 25 | SEC ↗ | |
| Chief Commercial Officer | Sale | 275 | $3K | Jun 5 | SEC ↗ | |
| Director | Sale | 2,811 | $39K | Jun 5 | SEC ↗ | |
Mensinger MikeFirst in 3 months | Chief Product Officer | Sale | 4,378 | $55K | Jun 3 | SEC ↗ |
| Chief Commercial Officer | Sale | 5,329 | $67K | Jun 3 | SEC ↗ | |
Saint SeanFirst in 3 months | President & CEO | Sale | 16,872 | $213K | Jun 3 | SEC ↗ |
| Chief Medical Officer | Sale | 4,222 | $53K | Jun 3 | SEC ↗ | |
Feider StephenFirst in 3 months | Chief Financial Officer | Sale | 6,676 | $84K | Jun 3 | SEC ↗ |
Jones ChristyFirst filing | Director | Sale | 1,998 | $20K | May 26 | SEC ↗ |
Lezack AdamFirst in 6 months | Director | Sale | 1,000 | $10K | May 26 | SEC ↗ |
Lezack AdamFirst in 6 months | Director | Sale | 998 | $11K | May 26 | SEC ↗ |
| Chief Commercial Officer | Sale | 856 | $25K | Mar 16 | SEC ↗ | |
| Chief Commercial Officer | Sale | 2,061 | $63K | Mar 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 1,025 | $30K | Mar 16 | SEC ↗ | |
| Chief Commercial Officer | Sale | 353 | $4K | Mar 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,428 | $18K | Mar 3 | SEC ↗ | |
| Chief Product Officer | Sale | 1,064 | $13K | Mar 3 | SEC ↗ | |
Hopman MarkFirst in 6 months | Chief Commercial Officer | Sale | 834 | $10K | Mar 3 | SEC ↗ |
| President & CEO | Sale | 3,384 | $42K | Mar 3 | SEC ↗ | |
Russell Steven JonFirst filing | Chief Medical Officer | Sale | 1,026 | $13K | Mar 3 | SEC ↗ |
| Chief Product Officer | Sale | 2,200 | $66K | Jan 7 | SEC ↗ | |
| Chief Financial Officer | Sale | 20,000 | $591K | Jan 5 | SEC ↗ | |
| Chief Product Officer | Sale | 7,800 | $231K | Jan 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,427 | $42K | Dec 4 | SEC ↗ | |
Saint SeanFirst filing | President & CEO | Sale | 3,278 | $96K | Dec 4 | SEC ↗ |
Mensinger MikeFirst filing | Chief Product Officer | Sale | 1,063 | $31K | Dec 4 | SEC ↗ |
| Director | Sale | 1,406 | $42K | Dec 2 | SEC ↗ | |
| Director | Sale | 1,406 | $42K | Dec 2 | SEC ↗ | |
Lezack AdamFirst filing | Director | Sale | 1,406 | $38K | Nov 5 | SEC ↗ |
Palasis MariaFirst filing | Director | Sale | 1,406 | $38K | Nov 5 | SEC ↗ |
| Chief Financial Officer | Sale | 4,982 | $108K | Oct 7 | SEC ↗ | |
| Chief Financial Officer | Sale | 15,018 | $312K | Oct 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 9,900 | $209K | Sep 9 | SEC ↗ | |
Hopman MarkFirst filing | Chief Commercial Officer | Sale | 6,818 | $136K | Sep 8 | SEC ↗ |
Hopman MarkFirst filing | Chief Commercial Officer | Sale | 11,411 | $235K | Sep 8 | SEC ↗ |
Feider StephenFirst filing | Chief Financial Officer | Sale | 100 | $2K | Sep 8 | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does BBNX have?
Beta Bionics, Inc. (BBNX) has 51 SEC Form 4 filings (82 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Sep 3, 2026.
When was the most recent SEC Form 4 filing for BBNX?
The most recent Form 4 filing for BBNX on Tracefour is dated Sep 3, 2026.
Who is the most active insider at BBNX?
The most active SEC Form 4 filer at BBNX in the rolling window is Chief Financial Officer Feider Stephen, with 11 filings.
What is the net insider flow at BBNX over the last 6 months?
Over the trailing 180 days, insiders at BBNX have net sold $1.6M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at BBNX in the current window?
Inside the rolling window, insiders at BBNX bought $0 and sold $3.9M based on SEC Form 4 filings.
Can I get alerts for BBNX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Beta Bionics, Inc. (BBNX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Beta Bionics, Inc. is in the Healthcare sector.